Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to Fibroblast Growth Factor 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (Fibroblast Growth Factor 1). Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials.
Basic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.